Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology

In today's rapidly changing and fiercely competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies. In this article, we will conduct a

BenzingaJul 16 23:00

Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling

The Nasdaq 100 closed higher by more than 100 points on Friday. Investors, meanwhile, focused on some notable insider trades.

BenzingaJul 15 20:19

CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,152

CCORF analyst John Newman maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and maintains the target price at $1,152.According to TipRanks data, the analyst has a success rate of 38.7%

Futu NewsJul 15 19:31 · Ratings

Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution

The fact that multiple Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When

Simply Wall StJul 15 18:42

US Stocks | Six-day consecutive rise! Rivian has surged nearly 35% this month; multiple pharmaceutical giants hit new highs! Eli Lilly and Co. maintains a market cap of 900 billion US dollars.

With the arrival of the tourism season, online travel giant Booking has reached a new high this year, rising nearly 17% since May. With better-than-expected performance, Bank of New York Mellon rose more than 5% after its results, and Goldman Sachs raised its target price.

Futu NewsJul 15 18:40

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years

Yahoo FinanceJul 14 21:00